LivaNova (NASDAQ:LIVN) Price Target Raised to $120.00

by · The Cerbat Gem

LivaNova (NASDAQ:LIVN – Free Report) had its target price hoisted by Barclays from $105.00 to $120.00 in a report issued on Monday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

A number of other equities analysts have also weighed in on the stock. Zacks Research lowered shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Raymond James Financial set a $120.00 price objective on LivaNova in a research report on Wednesday, November 4th. Piper Sandler reissued an “overweight” rating and issued a $90.00 target price (up from $87.00) on shares of LivaNova in a research note on Wednesday, September 2nd. Robert W. Baird increased their price objective on LivaNova from $95.00 to $111.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Finally, Stifel Nicolaus set a $85.00 price objective on LivaNova in a research report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $101.22.

Get Our Latest Research Report on LivaNova

LivaNova Trading Down 0.2%

NASDAQ:LIVN opened at $90.98 on Monday. The company has a market cap of $5.01 billion, a PE ratio of 24.97 and a beta of 0.91. The firm has a 50-day moving average of $79.96 and a 200-day moving average of $73.96. LivaNova has a one year low of $52.37 and a one year high of $99.38. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.46 and a quick ratio of 1.22.

LivaNova (NASDAQ:LIVN – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.17. The firm had revenue of $393.15 million for the quarter, compared to the consensus estimate of $381.13 million. LivaNova had a net margin of 13.01% and a return on equity of 16.10%. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.11 EPS. As a group, equities research analysts expect that LivaNova will post 3.79 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Francesco Bianchi sold 3,500 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the completion of the sale, the director owned 4,434 shares in the company, valued at approximately $345,896.34. This represents a 44.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brooke Story sold 2,300 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the sale, the director owned 7,488 shares of the company’s stock, valued at approximately $609,672.96. This represents a 23.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 7,450 shares of company stock worth $591,839. Company insiders own 0.35% of the company’s stock.

Institutional Investors Weigh In On LivaNova

Several large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its stake in shares of LivaNova by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company’s stock valued at $116,067,000 after acquiring an additional 38,320 shares during the period. Janus Henderson Group PLC boosted its position in shares of LivaNova by 1,978.8% in the 1st quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock worth $29,961,000 after purchasing an additional 448,703 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of LivaNova during the 1st quarter worth about $18,327,000. Sei Investments Co. grew its holdings in LivaNova by 56.6% in the first quarter. Sei Investments Co. now owns 218,805 shares of the company’s stock valued at $13,907,000 after purchasing an additional 79,088 shares during the period. Finally, Renaissance Technologies LLC grew its stake in LivaNova by 15.7% in the 1st quarter. Renaissance Technologies LLC now owns 183,000 shares of the company’s stock valued at $11,631,000 after acquiring an additional 24,900 shares during the period. Institutional investors own 97.64% of the company’s stock.

About LivaNova

(Get Free Report)

LivaNova plc is a global medical technology company that develops and manufactures products for cardiovascular care and neuromodulation. The company was formed in 2015 through the combination of Cyberonics and Sorin Group. In neuromodulation, LivaNova’s VNS Therapy system delivers vagus nerve stimulation and is used as an adjunctive treatment for certain people with drug-resistant epilepsy and treatment-resistant depression. Its cardiovascular products support cardiac surgery and include heart-lung machines, oxygenators and related perfusion equipment.

Read More